Advisory Board

ADC Review, Journal of Antibody-drug Conjugates Advisory Board is comprised of physicians, industry experts and Key Opinion Leaders (KOL) from a broad range of backgrounds and expertise that include:

Clinical oncology and hematology practice innovation, management, public policy, professional advocacy and education.
Actively managing successful clinical practices, teaching at major universities and hospitals, holding senior management positions at medical associations, research institutes / laboratories, pharmaceutical and life-science companies, governmental agencies and major insurance companies.
Impressive level of healthcare experience, enabling us to offer innovation, education, advocacy and best practices to our readers.

To join our advisory board, please contact:

Peter Hofland
Publisher and Executive Editor
[email protected]

Charles Afram, MSc, BSc

Medical Advisor Oncology at OnocNeth Partners and Nordic Pharma.

Read full profile

Clifford S. Mintz, PhD

A seasoned bioscience professional with over 18 years of experience in drug discovery/development, biomanufacturing, commercialization and regulatory compliance. Dr Mintz is also a professional medical/healthcare writer and a regular contributor to life sciences business publications.

Read full profile

Alain Beck, Ph.D

Senior Director Antibody and ADC Physico-Chemistry Centre d’Immunologie Pierre Fabre (CIPF) (Alain is also member of the World ADC Advisory Board).

Read full profile

Don S. Dizon, MD, FACP

Associate Professor of Obstetrics & Gynecology, Department: Obstetrics & Gynecology and Medicine, Brown University, Division of Biology and Medicine.

Read full profile

Dr. Penelope Drake

Dr. Penelope Drake is the Director of R&D at Catalent Biologics (formerly Redwood Bioscience) where she oversees the preclinical development of antibody-drug conjugate programs.

Read full profile

Laurent Ducry, Ph.D

Ducry joined Kodiak Sciences in 2019 as head of Biologics Development and Manufacturing, responsible for the global supply chain of Kodiak's bioconjugates (DS and DP). Kodiak is a clinical stage company developing innovative therapeutics to treat chronic, high prevalence ophthalmic diseases.

Read full profile

Alain Herrera, MD

Consultant in Oncology and Associate Director at Kephren in Paris, France.

Read full profile

Maria Fe Paz, MSc, Ph.D

Maria Fe Paz is, the Chief Medical Officer of Diaceutics Group responsible for the development of clinical and laboratory partnerships.

Read full profile

Prathap Kumar Mahalingaiah, DVM, MS, PhD, DABT

Prathap Kumar Mahalingaiah, DVM, MS, PhD, DABT is currently Senior Scientist Senior Scientist, Investigative Toxicology and Pathology at Abbvie.

Read full profile

Sanjay Nilapwar, Ph.D

Sanjay Nilapwar, Ph.D, works as Purification Process Scientist in Novel Molecules group of Medimmune, Gaithersburg and is also part of platform ADC CMC development team.

Read full profile

Thomas Rohrer, BS, MS

Head of Antibody Drug Conjugation Project Evaluation at Lonza, has 30 years of experience in development, scale-up and manufacturing.

Read full profile

Ian Schwartz

Ian Schwartz is Sartorius Stedim Biotech’s global bioconjugate technology consultant and advises bioconjugate companies around the world on process development, technology transfer and manufacturing scale up .

Read full profile

Thomas Shellenberger, MD

Surgical oncologist who focuses on cancers of and neck.

Read full profile

Ruta Waghmare, Ph.D

Ruta Waghmare (Ph.D) is the Vice President, Scientific Affairs and Laboratory Services at Pall Biotech.

Read full profile

Judith Wolf, MD

Board Certified Oncologists who received her medical education from the Northeastern Ohio Universities College of Medicine and the University of Texas Health Science Center at Houston.

Read full profile

Cynthia Wooge, Ph.D

Cynthia Wooge (Ph.D) has been in the pharmaceutical contract manufacturing for over 20 years, with diverse experience including custom product development, technology transfer, process validation to business development. Cynthia is currently Head of Process and Technology at MilliporeSigma, a devision of Merck KGaA.

Read full profile

Cecilia Zapata-Harms, MS, MHA

Cecilia Zapata-Harms (MS, MHA) is chief visionary office at ELEV8BIO. She has held leadership positions in strategy, joint venture startup and program administration. Her career spans more than 25+ years in life science/biotechnology and healthcare industry.